Cystitis medical therapy

Jump to navigation Jump to search
Urinary Tract Infections Main Page

Cystitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cystitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultarsound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Tests

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cystitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cystitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cystitis medical therapy

CDC on Cystitis medical therapy

Cystitis medical therapy in the news

Blogs on Cystitis medical therapy

Directions to Hospitals Treating Cystitis

Risk calculators and risk factors for Cystitis medical therapy

Steven C. Campbell, M.D., Ph.D.

Overview

Antimicrobial therapy is indicated in cystitis. The treatment of cystitis depends on the disease course (acute uncomplicated vs. complicated) and the rates of resistance in the community. Due to the risk of the infection spreading to the kidneys (complicated UTI) and the high complication rate in diabetics and the elderly population, prompt treatment is almost always recommended.

Principles of Medical Therapy

  • Symptomatic women with NO history of urinary tract infection or a lab-confirmed infection are recommended to undergo testing for urinary tract infection by urinalysis or dipstick testing for the detection of pyuria.
  • Symptomatic women who have had frequent recurrences in the past and prior confirmation of urinary tract infections may be treated empirically.
  • For women with first-time lower UTI, a urine culture is not required prior to administration of empiric therapy.
  • The choice of therapy depends on whether the patient has uncomplicated vs. complicated cystitis, known patient allergies, and regional resistance patterns as shown in the algorithm below:

Acute Uncomplicated Cystitis

  • Patients with acute uncomplicated cystitis may be treated using a single antimicrobial therapy using either a single dose or a 3-day regimen. The following list of antimicrobial agents may be administered:
  • Empiric Therapy:
  • Preferred regimen (1): Fosfomycin tromethamine 3 g PO single dose
  • Preferred regimen (2): Nitrofurantoin monohydrate/macrocrystals 100 mg PO bid for 5 days
  • Preferred regimen (3): Trimethoprim-Sulfamethoxazole 160/800 mg PO double-strength tablet bid for 3 days
  • Preferred regimen (4): Trimethoprim 100 mg PO bid for 3 days
  • Alternative regimen (1): Ciprofloxacin 250 mg PO bid for 3 days
  • Alternative regimen (2): Levofloxacin 250 mg PO qd for 3 days
  • Alternative regimen (3): Norfloxacin 400 mg PO bid for 3 days
  • Preferred regimen (8): Gatifloxacin 200 mg PO qd for 3 days
  • Note (1): Avoid Nitrofurantoin and Fosfomycin is pyelonephritis is suspected
  • Note (2): Avoid Trimethoprim-based regimens if resistance regional prevalence exceeds 20% or if patient had a prior UTI within the past 3 months
  • Note (3): β-lactam-based regimens are less effective than other available agents and are only indicated when other agents cannot be used.

Complicated Cystitis

Patients who meet at least one of the following criteria are considered to have complicated cystitis: [1]

  • Male gender
  • Pregnant women
  • Children with metabolic diseases
  • Children with genitourinary abnormalities
  • Patients suspected to be at high risk of developing complications or treatment failure, including:
  • Patients with urinary stone
  • Patients with neurogenic bladder
  • Immunocompromised patients
  • Renal failure patients
  • Transplant patients

Recurrent Cystitis

  • Patients with recurrent cystitis may require prolonged prophylactic antimicrobial therapy for 6-12 months.
  • The same antimicrobial agents that are indicated for uncomplicated cystitis are also indicated for recurrent cystitis.
  • Patients with recurrent cystitis should be re-evaluated at the time of completion of therapy.
  • Patients who develop recurrent UTI following sexual activity may benefit from prophylactic antimicrobial therapy. To view the list of regimens indicated for the primary prevention of cystitis, click here.

Cystitis in Pregnancy

==Empiric Therapy for Acute Cystitis== Adapted from Clin Infect Dis. 2011;52(5):e103-20.[4]


Acute Bacterial Uncomplicated Cystitis
Preferred Regimen
Nitrofurantoin 100 mg PO q12h × 5 days
OR
TMP 100 mg PO q12h ×3 days
OR
Fosfomycin 3 gm PO single dose
OR If resistence<20% or if used for UTI >3 months
TMP-SMX ‡ 1 DS tab PO q12h × 3 days
OR Not FDA approved but used in some European countries
Pivmecillinam 400 mg PO q12h 3-7 days
Alternative Regimen
Fluoroquinolones for 3 days
Ofloxacin 200–400 mg PO bid
OR
Ciprofloxacin 250 mg bid PO or Cipro XR 500 mg q24h
OR
Levofloxacin 250–750 mg PO q24
OR β-lactam agents for 3-7 days
Amoxicillin-clavulanate 500/125 mg PO q8h or 875/125 mg PO q8h
OR
Cefdinir 300 mg PO q12h or 600 mg PO q24
OR
Cefaclor 250-500 mg PO q8h
OR
Cefpodoxime proxetil 100-200 mg PO q12h
OR
Cephalexin250-500 mg PO q6h not studied well but effective.
Complicated/Catheter Associated Cystitis
Preferred Regimen
Mild Infection
Levofloxacin 750 mg PO q24 × 5 days
Delayed Response
Levofloxacin 750 mg PO q24 × 10-14 days
After Catheter Removal
Levofloxacin 750 mg PO q24 × 3 days
Acute Cystitis in Pregnancy
Preferred Regimen
Nitrofurantoin 100 mg PO q12h × 3-5 days
OR
Fosfomycin 3 g PO single dose
OR
Amoxicillin-clavulanate 500/125 mg PO q12h × 3-5 days
OR
Amoxicillin 500 mg PO q12h × 3-5 days
OR
Cephalexin 500 mg PO q12h × 3-5 days
OR
TMP-SMX DS 1 tab PO q12h × 3-5 days
avoid in first trimester(TMP) and third trimester (SMX).

References

  1. Hooton, TM. (2012). "Clinical practice. Uncomplicated urinary tract infection". N Engl J Med. 366 (11): 1028–37. doi:10.1056/NEJMcp1104429. PMID 22417256. Unknown parameter |month= ignored (help)
  2. Ben David, S.; Einarson, T.; Ben David, Y.; Nulman, I.; Pastuszak, A.; Koren, G. (1995). "The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis". Fundam Clin Pharmacol. 9 (5): 503–7. PMID 8617414.
  3. Crider, KS.; Cleves, MA.; Reefhuis, J.; Berry, RJ.; Hobbs, CA.; Hu, DJ. (2009). "Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study". Arch Pediatr Adolesc Med. 163 (11): 978–85. doi:10.1001/archpediatrics.2009.188. PMID 19884587. Unknown parameter |month= ignored (help)
  4. Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources